The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV. Learn more about your ad choices. Visit megaphone.fm/adchoices

We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development. Learn more about your ad choices. Visit megaphone.fm/adchoices

Several companies with product candidates in the posterior segment provide updates; Ocuphire acquires an ophthalmic gene therapy company; and Astellas provides an update on its regulatory plans for GA drug avacincaptad pegol. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago.

Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop. 

Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.

Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.   

Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system.

EyewireTV reports on new products and breaking news live from the European Society of Cataract and Refractive Surgeons Congress in Barcelona.

Zeiss Lenticule Extraction for Hyperopia • Alcon Ngenuity 1.5 • Oculus Pentacam Cornea OCT • Lensar ALLY Adaptive Cataract Treatment System • BVI Serenity IOLs • Topcon TRK-Omnia

First Therapy for Acanthamoeba Keratitis Approved in Europe • Oculus Adds Dual Testing Functionality to Easyfield VR • FDA Clears IND Application for Stem Cell Therapy for Primary Photoreceptor Diseases

Rayner Unveils First AI-Designed Spiral IOL • Visionix Launches VX 610 Non-Mydriatic Automated Fundus Camera • Injectsense Completes First Human Implant of Ultraminiature IOP Sensor

Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations • Ultrasonic Sensor Device Launched for Loss of Side Vision • Ocuvex Therapeutics Acquires Visiox Pharmaceuticals

Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop

Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin • Wearable Aid with AI-Powered Visual Assistant is Unveiled • ASCRS Business of Refractive Cataract Surgery Summit Launched